Sumanta Kumar Pal, M.D.

  • Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
  • Co-director, Kidney Cancer Program
  • Medical Oncologist

Sumanta Kumar Pal, M.D.

  • Medical Oncology
  • Urology and Urologic Oncology
  • Prostate Cancer
  • Bladder Cancer
  • Kidney Cancer
  • Urology and Urologic Oncology
  • Spanish
Sumanta (Monty) Kumar Pal, M.D., was studying medicine when most of his peers were worrying about their acne.
A child prodigy, he was only 13 when he started college. He entered David Geffen School of Medicine at UCLA at 17. At City of Hope since 2009, Dr. Pal enjoys being called the “youthful oncologist,” though his research output belies his young years; he has published more than 80 papers in peer-reviewed journals and presented his work in numerous forums around the world.
Dr. Pal has been cited for his outstanding work in bladder, kidney and prostate cancer research. His ultimate goal is to take discoveries in the laboratory and translate them quickly and efficiently into tangible benefits for patients. He is fascinated by new research pointing to a possible link between male pattern baldness and prostate cancer.
  • 2009 - present, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2009 - present, Co-director, Kidney Cancers Program, City of Hope, Duarte, CA
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Testicular Cancer
  • Urology and Urologic Cancers


1500 East Duarte Road, Duarte, CA, 91010


電話 :  626-256-4673


  • 2003, David Geffen School of Medicine at UCLA, Los Angeles, CA, M.D.
  • 1998, California State University, Los Angeles Early Entrance Program, College in lieu of high school (program initiated at age 13)
  • Magna Cum Laude, B.Sc.


  • 2006 -2009, Fellowship in Hematology/Oncology, City of Hope/Harbor-UCLA Medical Center, Los Angeles, CA


  • 2003 -2006, Residency in Internal Medicine, UCLA Medical Center, Los Angeles, CA
  • 2006-present, American Society of Clinical Oncology (ASCO) (2006- present)
  • National Comprehensive Cancer Network Bladder Cancer Committee (2010-present)
  • HER2-Positive Breast Cancer Committee, ASCO (2012-2013)
  • Genitourinary Cancers Committee, ASCO (2013-present )